Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2017-02-24 Capital/Financing Update
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM F-1
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 registration statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for Bioblast Pharma Ltd. The text includes details about the offering of ordinary shares, underwriting, risk factors, business overview, and financial data. Form F-1 is used for initial public offerings (IPOs) or other securities registrations by foreign private issuers. This type of filing is a capital markets document related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2017-02-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Bioblast Pharma Ltd., submitted to the SEC. It includes a press release announcing financial results for the fourth quarter and full year ended December 31, 2016. The document is relatively short (2433 characters) and primarily serves to announce the financial results rather than containing the full detailed financial statements or comprehensive analysis itself. The text states that the press release is attached as Exhibit 99.1 and that the financial statements are incorporated by reference into other registration statements. This indicates the document is an announcement of financial results rather than the full report. Form 6-K filings typically serve as current reports for foreign issuers and often contain announcements or updates rather than full annual or interim reports. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other specific categories and includes current reports like Form 6-K that announce financial results without full detailed financial data.
2017-02-24 English
AMENDED SC 13G
Major Shareholding Notification
2017-02-15 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing Phase 2a clinical trial results for a drug, which is a typical content for a 6-K. The document is short (2393 characters) and primarily serves as a regulatory announcement of the press release rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed analysis. It also does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial data. Given the nature of Form 6-K filings as periodic regulatory disclosures for foreign issuers, and the content being a press release announcement, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-01-18 English
SABBY 13G-A ORPN 1.10.17
Major Shareholding Notification
2017-01-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Bioblast Pharma Ltd., submitted to the SEC. It includes a press release announcing financial results for the third quarter ended September 30, 2016. The document length is 2475 characters, which is relatively short and primarily serves to announce the attached press release rather than containing detailed financial statements or analysis itself. The text states that the press release is attached as Exhibit 99.1, indicating this document is an announcement of the financial results rather than the full interim or quarterly report. According to the 'Menu vs Meal' rule, short documents that announce or attach reports are classified as Regulatory Filings (RNS) rather than Interim/Quarterly Reports (IR). Therefore, this document should be classified as Regulatory Filings (RNS).
2016-11-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.